Xenetic Bio Share Discussion Threads

[ashthorpedo] 29/5/2014 12:25

This invitation-only event attracts top fund managers and qualified high net worth investors who focus on small cap equities. One-on-one meetings are available for company management teams and qualified investors. - See more at: hxxp://www.marcumllp.com/microcap/#sthash.B2NoPqWV.dpuf

[ashthorpedo] 29/5/2014 12:23

Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that the Company will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.

The Company's presentation by Scott Maguire, CEO of Xenetic, is scheduled to begin at 11:30 a.m. EDT and will be available via a live webcast. To access the webcast, go to hxxp://ir.xeneticbio.com/ or hxxp://wsw.com/webcast/marcum2/xbio/.

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than $500 million in market capitalization. For more information or to register, please visit the conference website at hxxp://www.marcumllp.com/microcap/.

[digger18] 29/5/2014 10:13

Baxter are certainly keen on the company and have demonstrated this with the 10Mil shares @ a premium. Don't forget that we will also receive royalties from any advanced sales in Russia and India as they will probably be able to take to market faster. It will be also interesting to what comes out of the pot regarding a "new cancer indication" with Oncohist.

[buywell2] 29/5/2014 07:36

ErepoXen® Phase 2 results should be good

Don't forget this is NOT a new drug molecule but uses Xenetic Technology to re-formulate it so that it's efficacy is improved.

Present treatments for chronic renal treatment involve much more intensive treatments and administrations of drugs ... ErepoXen® will have better efficacy and need much fewer treatments/administrations by nursing staff , a win/win , it will also no doubt be marketed cheaper than existing chronic renal drugs as there is NO MASSIVE R&D costs of $1.5 BILLIONS (average) to recover. So a win/win/win ... will Baxter be the Western partner to go to Phase 3 trials ?

[digger18] 28/5/2014 20:42

Eropoxen Aus results are key,as success will hopefully lead to a Pharma deal that will mitigate the need for further finance raising and possible dilution. Exciting times ahead.

[jammytass] 28/5/2014 20:13

yip spot on guys nasdaq listing will follow a major rns hold tight!!!!

[audigger] 28/5/2014 20:10

NASDAQ would make it more attractive in terms of liquidity but I think now is the time in terms of the opportunity. I think TD-Direct offer US OTC so may take the plunge. Certainly won't be going in to an ISA! I assume you have to buy in USD which means exchange rate costs with each trade and of course they are vulnerable to any longer term currency fluctuations, but that should be small beer compared to the potential share price increase!

[buywell2] 28/5/2014 17:55

Not easy at present to deal in the USA OTC exchange using pink tickets but I think Barclays can

I think there will be two candidates through Phase 2 by xmas this year

Big Pharma then to partner for Phase 3's

they plan to list on NASDAQ as a Management priority

[audigger] 28/5/2014 10:34

So Buywell are these worth a punt? Been watching these for a while and am now tempted as the technology looks exciting.

[buywell2] 22/5/2014 18:40

Yes I know

My point is

where Baxter has led others may follow

As Xenetic IP & Patents continue to grow

[holly_dog] 22/5/2014 18:07

They did but that is an off-market fund-raising, no relevance whatsoever to the current order book. We need news to attract more buying. Hopefully NASDAQ is edging closer

[buywell2] 22/5/2014 17:45

Baxter paid $1 did they not for 10,000,000

[holly_dog] 22/5/2014 17:42

Going to need a determined buyer to push the price up.

6 MMs on the sell side from 0.80 to 0.94 and a whopper 216k sell order at 0.94 as well.

[buywell2] 22/5/2014 16:40

Wonder which will come first

Cash from India sales or from Russia ?

My guess would be India .... but they have been taking their bloody time over there

Perhaps our Russian State partners and majority shareholders could give them a shove

[holly_dog] 22/5/2014 09:04

Nothing yesterday. There was 100k on the ask at 95c all day. BKRT were still on the bid at 85c but were not active.

[buywell2] 22/5/2014 08:46

Re the above

The Xenetic BioSciences CEO has now stated that XBIO will be seeking a NASDAQ Listing as 'one of the primary goals of management and the Board'

This will OPEN the company up to a MASSIVE number of NEW Investors that have never even heard of them.

This new cancer indication for OncoHist could well turn out to be a BIGGIE if as the company says it manages to get U.S. Orphan Drug Designation for it

$10m plus in the bank cash for now to fund above.

Another milestone from Baxter also when clinical trials start which must be fairly soon now .... by xmas this year I would have thought

[buywell2] 22/5/2014 07:10

Some good stuff here


Expected 2014 Milestones

• Present interim data from Phase 2 Australia/New Zealand trial of ErepoXen® for the treatment of chronic anemia in patients with renal disease
• Advance ongoing clinical development of OncoHist®, with planned U.S. IND filings for AML and an additional cancer indication
• Secure U.S. Orphan Drug Designation for additional oncology indication for OncoHist®
• Present interim data from Phase 2 Russia trial of OncoHist® in patients with refractory AML and Non Hodgkin's Lymphoma
• Initiate Phase 2 trial of PulmoXen® for the treatment of cystic fibrosis, conducted by Russian partner, OJSC Pharmsynthez
• Commence IV trials for ErepoXen® for in-center dialysis patients in India based on Xenetic's positive Phase 2 data for pre-dialysis patients
• In addition to these expected milestones, one of the primary goals of management and the Board is to seek a NASDAQ Capital Market uplist at the earliest practical date

[corrientes] 20/5/2014 22:12

Wonder who tipped it ?

[bobsgonnamakemerich] 20/5/2014 20:47

I would love to see the volume at this level being normal, very reassuring.

[holly_dog] 20/5/2014 18:33

Smashing it. 80k volume. Best in months. Been following on L2, BKRT who seem to act for institutions / funds have been on the bid all day soaking up a ton of sells. Now sitting on it at 87c. Very promising, hopefully news is imminent or we finally have a US institution taking a stake

[jammytass] 20/5/2014 17:42

up 47 percent in us tday

[corrientes] 20/5/2014 16:51

A bit better

[buywell2] 14/5/2014 07:18

No problem with that

More News soon